Skip to main content
Berry Genomics Co.,Ltd logo

Berry Genomics Co.,Ltd — Investor Relations & Filings

Ticker · 000710 ISIN · CNE000000PN7 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,009 across all filing types
Latest filing 2020-12-09 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000710

About Berry Genomics Co.,Ltd

https://www.berrygenomics.com

Berry Genomics Co.,Ltd. is a biotechnology enterprise specializing in clinical genomics and genetic testing services. The company focuses on the research, development, and commercialization of genomic technologies for clinical applications. Its core portfolio includes non-invasive prenatal testing (NIPT), utilizing high-throughput sequencing to screen for chromosomal abnormalities. Beyond reproductive health, the company provides genomic solutions for oncology diagnostics, including early cancer screening and companion diagnostics, as well as testing for hereditary diseases. Berry Genomics leverages advanced sequencing platforms and proprietary bioinformatics pipelines to deliver precision medicine tools to healthcare providers and research institutions. The company is recognized for its role in the clinical application of Next-Generation Sequencing (NGS) and its extensive genomic databases used to enhance diagnostic accuracy and therapeutic outcomes.

Recent filings

Filing Released Lang Actions
独立董事关于第九届董事会第五次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion regarding a board meeting decision about the company's transaction involving the transfer of a controlling stake in a subsidiary. It references compliance with company law, stock exchange listing rules, and governance guidelines. The content focuses on the board's approval and the independent directors' agreement on the transaction's fairness and legality. There is no financial statement, earnings data, or detailed report content. The document is a board/management related announcement about a corporate transaction and board meeting matters, not a full report or financial disclosure. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Confidence is high due to clear references to board meeting and independent directors' opinion on a transaction.
2020-12-09 Chinese
关于股份回购期限届满暨股份回购实施结果的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the completion of a share repurchase program by the company. It details the number of shares repurchased, the price range, compliance with regulatory rules, and the impact on the company's shareholding structure. It also references previous announcements about the repurchase progress and shareholder transactions. The document does not contain financial statements or detailed financial analysis but focuses on the share buyback activity and its results. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back its own shares.
2020-12-07 Chinese
关于持股5%以上的股东减持股份的预披露公告
Major Shareholding Notification Classification · 95% confidence The document is a pre-disclosure announcement regarding the planned reduction of shareholding by a shareholder holding more than 5% of the company's shares. It details the shareholder's name, shareholding percentage, planned reduction amount, period, method, and risk warnings. The document does not contain financial statements or detailed financial performance data but is an official announcement about a significant shareholder's planned share reduction. This fits the definition of a Major Shareholding Notification (MRQ). The document length is short (1755 characters), and it is not a report publication or certification. Therefore, the correct classification is MRQ with high confidence.
2020-12-07 Chinese
关于持股5%以上股东减持股份的预披露公告
Major Shareholding Notification Classification · 100% confidence The document is a pre-disclosure announcement regarding the planned reduction of shares held by a shareholder owning more than 5% of the company. It details the shareholder's name, shareholding percentage, planned reduction amount, period, and method of share reduction. The document includes risk warnings and compliance with stock exchange rules. It does not contain financial statements, earnings data, or management discussion. It is a notification about a major shareholder's transaction intentions, which fits the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, not a full report or announcement of a report publication.
2020-12-04 Chinese
关于持股5%以上股东减持计划实施期限届满暨实施结果的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the implementation period expiration and results of a shareholding reduction plan by a shareholder holding more than 5% of the company's shares. It details the shareholder's name, shareholding percentages before and after the reduction plan, and confirms no shares were actually reduced during the plan period. The document is regulatory in nature, reporting insider shareholding changes but not a direct insider transaction report (which would be DIRS). It is not a full financial report, earnings release, or management discussion. It fits best as a Major Shareholding Notification (MRQ) because it concerns a significant shareholder's shareholding status and changes (or lack thereof). The document length is short and focused on shareholding changes, not a full report or announcement of a report publication. Therefore, the classification is MRQ with high confidence.
2020-12-03 Chinese
关于公司2020年度非公开发行股票申请文件反馈意见的回复
Capital/Financing Update Classification · 95% confidence The document is a detailed response to feedback from the China Securities Regulatory Commission regarding a 2020 non-public stock issuance application by Chengdu Berry Genomics Co., Ltd. It includes extensive information on the use of proceeds, investment amounts, capital expenditures, and project details related to the fundraising. The content focuses on the company's capital raising activities, investment plans, and use of funds, which aligns with updates on company fundraising and capital structure changes. It is not an annual report, earnings release, or management discussion, but rather a capital/financing update related to a specific stock issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is not a mere announcement but a substantive filing.
2020-12-03 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.